Patents by Inventor William D. Lubell

William D. Lubell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic peptides and uses thereof
    Patent number: 11879021
    Abstract: Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related diseases, disorders or conditions in a subject, such as atherosclerosis and age-related macular degeneration.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 23, 2024
    Inventors: William D. Lubell, Huy Ong, Jinqiang Zhang, Dilan Mukandila Mulumba, Sylvie Marleau, Ragnhild Gaard Ohm, Ahsanullah, Samy Omri, Ramesh Chingle
  • Methods for Reducing Perinatal Morbidity and / or Mortality
    Publication number: 20210322509
    Abstract: A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof: to an expectant human mother suffering from antenatal fetal inflammation. The method prevents or reduces the risk of organ damages, including brain, lung and intestinal damages, and sequelae therefrom, in the neonates, as well as the risk of neonatal death.
    Type: Application
    Filed: June 30, 2021
    Publication date: October 21, 2021
    Applicants: CHU SAINTE-JUSTINE, UNIVERSITÉ DE MONTRÉAL, THE UNIVERSITY OF ADELAIDE
    Inventors: Sylvain CHEMTOB, Christiane QUINIOU, Sarah Anne ROBERTSON, Mathieu NADEAU-VALLÉE, William D. LUBELL, David OLSON, Peck Yin CHIN, Sylvie GIRARD, Doan-Ngoc DUC
  • NOVEL CYCLIC PEPTIDES AND USES THEREOF
    Publication number: 20190202863
    Abstract: Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related diseases, disorders or conditions in a subject, such as atherosclerosis and age-related macular degeneration.
    Type: Application
    Filed: June 28, 2017
    Publication date: July 4, 2019
    Inventors: WILLIAM D. LUBELL, HUY ONG, JINQIANG ZHANG, DILAN MUKANDILA MULUMBA, SYLVIE MARLEAU, RAGNHILD GAARD OHM, AHSANULLAH, SAMY OMRI, RAMESH CHINGLE
  • METHODS FOR REDUCING PERINATAL MORBIDITY AND/OR MORTALITY
    Publication number: 20190091279
    Abstract: A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof to an expectant human mother suffering from antenatal fetal inflammation. The method prevents or reduces the risk of organ damages, including brain, lung and intestinal damages, and sequelae therefrom, in the neonates, as well as the risk of neonatal death.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 28, 2019
    Inventors: Sylvain CHEMTOB, Christiane QUINIOU, Sarah Anne ROBERTSON, Mathieu NADEAU-VALLÉE, William D. LUBELL, David OLSON, Peck Yin CHIN, Sylvie GIRARD, Doan-Ngoc DUC
  • Cinnamoyl inhibitors of transglutaminase
    Patent number: 9162991
    Abstract: A compound of Formula I or Formula II:
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: October 20, 2015
    Assignee: University of Ottawa
    Inventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
  • Peptidomimetics comprising N-amino cyclic urea residues and uses thereof
    Patent number: 8993515
    Abstract: Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed. Use of such peptidomimetics for modulating the activity of CD36 or IL-1 receptor in a cell, and for treating CD36- or IL-1-related disease, disorder or condition is also described.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: March 31, 2015
    Assignees: Valorisation-Recherche, Limited Partnership, RSEM, Limited Partnership
    Inventors: William D. Lubell, Sylvain Chemtob, Huy Ong, Robert Hopewell, Caroline Proulx, Kim Beauregard, Yesica Garcia-Ramos, Ngoc-Duc Doan
  • Prostaglandin-F2 alpha receptor modulators and uses thereof
    Patent number: 8802818
    Abstract: Prostaglandin-F2 alpha (PGF2?) receptor (FP) modulators of formula I, as well as the use of PGF2? receptor modulators for the treatment of conditions associated with FP activity such as preterm labor and colorectal cancer, are disclosed.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: August 12, 2014
    Inventors: William D. Lubell, Sylvain Chemtob, Terence E. Hebert, Audrey Claing, Stephane Laporte, Carine B. Bourguet, Eugenie Goupil, Xin Hou, Danae Tassy
  • PEPTIDOMIMETICS COMPRISING N-AMINO CYCLIC UREA RESIDUES AND USES THEREOF
    Publication number: 20140024606
    Abstract: Novel peptidomimetics comprising N-amino cyclic urea residues are disclosed.
    Type: Application
    Filed: June 5, 2013
    Publication date: January 23, 2014
    Inventors: WILLIAM D. LUBELL, SYLVAIN CHEMTOB, HUY ONG, ROBERT HOPEWELL, CAROLINE PROULX, KIM BEAUREGARD, YESICA GARCIA-RAMOS, NGOC-DUC DOAN
  • CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE
    Publication number: 20140024837
    Abstract: A compound of Formula I or Formula II:
    Type: Application
    Filed: August 30, 2013
    Publication date: January 23, 2014
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
  • Interleukin-1 receptor antagonists, compositions, and methods of treatment
    Patent number: 8618054
    Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: December 31, 2013
    Assignees: Valorisation-Rechereche Société en Commandite, Valorisation HSJ, Société en Commandite
    Inventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell, Martin Beauchamp, Karl A. Hansford
  • Cinnamoyl inhibitors of transglutaminase
    Patent number: 8614233
    Abstract: A compound of Formula, (I) or Formula: (II).
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: December 24, 2013
    Assignee: Universite de Montreal
    Inventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
  • PROSTAGLANDIN-F2 ALPHA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20120309690
    Abstract: Prostaglandin-F2 alpha (PGF2?) receptor (FP) modulators of formula I, as well as the use of PGF2? receptor modulators for the treatment of conditions associated with FP activity such as preterm labor and colorectal cancer, are disclosed.
    Type: Application
    Filed: June 1, 2012
    Publication date: December 6, 2012
    Inventors: William D. LUBELL, Sylvain CHEMTOB, Terence E. HÉBERT, Audrey CLAING, Stephane LAPORTE, Carine B. BOURGUET, Eugenie GOUPIL, Xin HOU, Danae TASSY
  • CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE
    Publication number: 20100204280
    Abstract: A compound of Formula, (I) or Formula: (II)
    Type: Application
    Filed: May 29, 2008
    Publication date: August 12, 2010
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
  • IL-23 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20100190710
    Abstract: The present invention relates to IL-23 receptor antagonists and agonists. The use of IL-23 receptor antagonists in treating autoimmune and inflammatory disorders, as well as methods of identifying IL-23 receptor antagonists and agonists.
    Type: Application
    Filed: July 7, 2008
    Publication date: July 29, 2010
    Applicant: Valorisation HSJ, Societe en Commandite
    Inventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell
  • INTERLEUKIN-1 RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS OF TREATMENT
    Publication number: 20100041609
    Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.
    Type: Application
    Filed: October 15, 2009
    Publication date: February 18, 2010
    Applicant: Valorisation-Recherche, Societe en Commandite
    Inventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell, Martin Beauchamp, Karl A. Hansford
  • 1,4-Substituted cyclohexane derivatives
    Publication number: 20040138272
    Abstract: Allylic compounds represented by the formula (I) are provided, 1
    Type: Application
    Filed: August 29, 2003
    Publication date: July 15, 2004
    Inventors: Lisa McKerracher, Eryk Thouin, William D. Lubell